Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Polycystic Ovary Syndrome

Interventions

DRUG

rosiglitazone

4 mg daily for 6 months

DRUG

drospirenone/ethinyl estradiol

1 tab (3mg/30mcg) daily for 6 months

Trial Locations (1)

Children's Hospital of Pittsburgh, Pittsburgh

All Listed Sponsors

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Silva Arslanian

OTHER

NCT00640224 - Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study | Biotech Hunter | Biotech Hunter